EUVIMEDEUVIMED entdecken
VergleichsstudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma

Benjamin Hebraud, Charis Charalampous, Ricardo Parrondo, Saurabh Chhabra, Madhu Nagaraj, Marco DiBonaventura, Mei Sheng Duh, Priyanka J Bobbili, Aolin Wang, Stephanie Frey-Koba, Joseph Milce, Maude Levy und 8 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · e780-e792.e7

DOI: 10.1016/j.clml.2026.03.014 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Benjamin Hebraud und 19 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France. Hauptthemen laut MEDLINE: Multiple Myeloma, Patient Reported Outcome Measures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaPatient Reported Outcome MeasuresHumansFemaleMaleAgedMiddle AgedQuality of LifeProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

B-cell maturation antigen (BCMA)Bispecific antibodyPatient reported outcomes (PRO)Triple-class refractory multiple myeloma

Autor:innen und Institutionen

  • Hematology Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Division of Hematology, Mayo Clinic, Rochester, Rochester, MN.
  • Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
  • Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Phoenix, AZ.
  • Pfizer Inc, New York, NY. Electronic address: marco.dibonaventura@pfizer.com.
  • Analysis Group, Inc, Boston, MA.

Förderung

  • Pfizer Inc

Zitieren

APA

Hebraud, B., Charalampous, C., Parrondo, R., Chhabra, S., Nagaraj, M., DiBonaventura, M., Duh, M. S., Bobbili, P. J., Wang, A., Frey-Koba, S., Milce, J., Levy, M., Chafetz, L., Faucher, A., Johnson, S. M. A., Hlavacek, P., Cislo, P., Hughes, D., Nador, G., & Kumar, S. K. (2026). Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 26(6), e780-e792.e7. https://doi.org/10.1016/j.clml.2026.03.014

Vancouver

Hebraud B, Charalampous C, Parrondo R, Chhabra S, Nagaraj M, DiBonaventura M, et al. Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):e780-e792.e7. doi:10.1016/j.clml.2026.03.014

BibTeX
@article{Hebraud2026,
  author = {Hebraud, Benjamin and Charalampous, Charis and Parrondo, Ricardo and Chhabra, Saurabh and Nagaraj, Madhu and DiBonaventura, Marco and Duh, Mei Sheng and Bobbili, Priyanka J and Wang, Aolin and Frey-Koba, Stephanie and Milce, Joseph and Levy, Maude and Chafetz, Lily and Faucher, Ariane and Johnson, Sarasa M A and Hlavacek, Patrick and Cislo, Paul and Hughes, David and Nador, Guido and Kumar, Shaji K},
  title = {Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {e780--e792.e7},
  doi = {10.1016/j.clml.2026.03.014}
}
Kostenlos starten →